Bloomberg Intelligence Lilly’s Zepbound Cuts Risk of Diabetes
Aug 20, 2024
Sam Fazeli, Director of Research for Global Industries at Bloomberg Intelligence, reveals how Eli Lilly’s Zepbound drug significantly reduces diabetes risk. Craig Trudell discusses the European Union's looming 9% tariff on Tesla imports from China, raising concerns about market competitiveness. Dryden Pence shares insights on current market dynamics and investment strategies, including how labor data and consumer trends are shifting the landscape, while also highlighting opportunities in AI venture capital.
Chapters
Transcript
Episode notes
1 2 3 4 5 6 7 8 9
Intro
00:00 • 2min
Eli Lilly's Obesity Drugs and Diabetes Management
01:59 • 13min
Tesla's Market Challenges in Europe and the Implications of Tariffs
14:56 • 4min
Market Insights and Consumer Trends
18:37 • 7min
Chipotle's Competitive Advantage Through Consumer Focus
25:42 • 2min
Navigating AI Venture Capital
27:25 • 6min
Investing in Innovative Vertical Software Solutions
33:41 • 4min
Navigating Market Volatility
37:23 • 9min
Anticipating Economic Signals from Jackson Hole
45:53 • 2min